protein kinase domain containing, cytoplasmicGenealiases: RLSDF · SGK493 · Vlk
Q-omics provides the consensus-scored PKDCC profile across patient tissues and cancer cell-line models. PKDCC expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PKDCC is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PKDCC RNA expression shows 17,030 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LUAD, and TGCT as cancer lineages where PKDCC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKDCC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKDCC survival associations across molecular data types. PKDCC RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKDCC RNA expression–survival associations across cancer types. High PKDCC expression shows unfavorable associations in MESO, BLCA, THCA and COAD, but favorable associations in UCEC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for PKDCC RNA expression.
This table summarizes PKDCC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PKDCC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKDCC shows lower tumor expression in LUAD, THCA, BLCA and LUSC and higher tumor expression in KIRC and LIHC. The LUAD box plot shows higher PKDCC RNA expression in normal versus tumor tissue (log2 FC = −1.970, t-test p < 0.001).
This table shows molecular features associated with PKDCC in patient tissues and cancer cell lines. In patient samples, PKDCC shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PKDCC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
